logo

Sage Therapeutics, Inc. (SAGE)



Trade SAGE now with
  Date
  Headline
6/12/2018 6:32:24 AM Sage Announces Pivotal Phase 3 Trial Status For SAGE-217
5/30/2018 7:07:07 AM Sage Therapeutics: FDA Acceptance Of NDA Filing & Grant Of Priority Review For Brexanolone IV In Postpartum Depression
5/3/2018 6:37:56 AM Sage Therapeutics Q1 Net Loss $74.6 Mln Vs Loss Of $56.8 Mln Last Year
4/23/2018 7:04:15 AM Sage Therapeutics Submits NDA To US FDA For Intravenous Brexanolone In Treatment Of Postpartum Depression
2/22/2018 6:38:47 AM Sage Therapeutics Q4 Net Loss $69.4 Mln Vs Net Loss $55.9 Mln Last Year
2/8/2018 10:16:04 PM Sage Therapeutics Prices Offering Of 3.51 Mln Shares At $164.00/shr
2/7/2018 6:32:45 AM Sage Therapeutics Receives FDA Breakthrough Therapy Designation For SAGE-217 For Major Depressive Disorder
1/31/2018 6:08:07 AM Sage Therapeutics Announces Positive Results From Placebo-Controlled Trial; SAGE-217 Meets Primary Endpoint
12/28/2017 4:26:12 AM Watch These 6 Biotech Stocks
12/7/2017 6:12:36 AM Sage Therapeutics Announces Positive Top-line Results From Phase 2 Placebo-controlled Clinical Trial Of SAGE-217
11/27/2017 12:02:55 PM RBC Capital Markets Is Raising SAGE Therapeutics, Inc. (SAGE) FY19 Rev. Estimate To 172.8 M From 165.3 M
11/27/2017 12:02:36 PM RBC Capital Markets Is Increasing SAGE Therapeutics, Inc. (SAGE) FY18 Rev. Estimate To 83.8 M From 76.3 M